Aronow Wilbert S
Departments of Medicine and Cardiology, Westchester Medical Center and New York Medical College, Macy Pavilion, Room 141, 10595, Valhalla, NY, USA.
Am J Prev Cardiol. 2020 May 1;1:100001. doi: 10.1016/j.ajpc.2020.100001. eCollection 2020 Mar.
Hypertension is the leading modifiable risk factor for cardiovascular events and mortality in the world. Hypertension is a major risk factor for cardiovascular events and mortality in the elderly. The 2017 American College of Cardiology/American Heart Association hypertension guidelines recommend treatment of noninstitutionalized ambulatory community-dwelling persons aged 65 years and older with an average systolic blood pressure of 130 mm Hg or higher or a diastolic blood pressure of 80 mm Hg or higher with lifestyle measures plus antihypertensive drug to lower the blood pressure to less than 130/80 mm Hg For elderly adults with hypertension and a high burden of comorbidities and limited life expectancy, clinical judgment, patient preference, and a team-based approach to assess risk/benefit is reasonable for decisions about the intensity of SBP lowering and the choice of antihypertensive drugs to use for treatment. Randomized clinical trials need to be performed in frail elderly patients with hypertension living in nursing homes. Elderly frail persons with prevalent and frequent falls, marked cognitive impairment, and multiple comorbidities requiring multiple antihypertensive drugs also need to be included in randomized clinical trials. Data on patients older than 85 years treated for hypertension are also sparse. These patients need clinical trial data. Finally, the effect of different antihypertensive drugs on clinical outcomes including serious adverse events needs to be investigated in elderly frail patients with hypertension and different comorbidities.
高血压是全球心血管事件和死亡的主要可改变风险因素。高血压是老年人发生心血管事件和死亡的主要风险因素。2017年美国心脏病学会/美国心脏协会高血压指南建议,对年龄在65岁及以上、平均收缩压为130毫米汞柱或更高或舒张压为80毫米汞柱或更高的非机构化门诊社区居住者,采用生活方式干预措施加用降压药物进行治疗,将血压降至低于130/80毫米汞柱。对于患有高血压且合并症负担重、预期寿命有限的老年人,临床判断、患者偏好以及基于团队的风险/获益评估方法对于决定收缩压降低的强度和用于治疗的降压药物选择是合理的。需要对居住在养老院的体弱老年高血压患者进行随机临床试验。随机临床试验还应纳入有跌倒史且频繁跌倒、有明显认知障碍以及需要多种降压药物治疗的多种合并症的体弱老年人。关于85岁以上高血压患者治疗的数据也很稀少。这些患者需要临床试验数据。最后,需要在患有高血压和不同合并症的体弱老年患者中研究不同降压药物对包括严重不良事件在内的临床结局的影响。